Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials
A 2025 systematic review of four randomized controlled trials involving 27,617 participants showed that semaglutide reduces MACE by 19% (relative risk 0.81, 95% CI 0.74-0.88), with additional benefits for cardiovascular death and nonfatal heart attack
One consistent theme across studies is that when patients stop these medications, weight regain is common
That is a category-level quality signal worth weighing
Melena is black, tarry stool from digested blood, often linked with upper digestive bleeding
These beverages also add empty calories that dont contribute to satiety, making it easier to overconsume without realizing it